With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.132710-90-8,1-Boc-4-(3-hydroxypropyl)piperazine,as a common compound, the synthetic route is as follows.
2-Chloro-1-fluoro-4-nitrobenzene (320 mg) and sodium hydride (60% in oil, 83 mg) were added to a THF (3 mL) solution of tert-butyl 4-(3-hydroxypropyl)piperazine-1-carboxylate (310 mg) at room temperature, and the reaction mixture was stirred at 70C overnight. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated brine, was dried over sodium sulfate, and was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: hexane-ethyl acetate) to obtain the target compound. 1H-NMR (CDCl3) delta 1.46 (9H, s), 1.94-2.04 (2H, m), 2.36-2.44 (4H, m), 2.51 (2H, t, J = 7.1 Hz), 3.44 (4H, br-s), 4.11 (2H, t, J = 6.2 Hz), 6.87 (1H, dd, J = 9.2, 2.6 Hz), 7.03 (1H, d, J = 2.6 Hz), 8.00 (1H, d, J = 9.2 Hz). LCMS (B) RT 1.01, m/z [M+H] +400/402., 132710-90-8
The synthetic route of 132710-90-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Taiho Pharmaceutical Co., Ltd.; MINAMIGUCHI, Kazuhisa; OKAJIMA, Shigeo; ASAI, Takahiro; ASAI, Masanori; OGINO, Yoshio; (80 pag.)EP3381916; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics